Come learn about the SPRING Trial (acute SCI)
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.
Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For seven years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. For additional information and the latest updates from the company, please visit www.vrtx.com.
Vertex initiated a Phase 2b/3 study with VX-210 in patients with acute traumatic cervical spinal cord injury (SCI) in 2016. This study is known as the SPRING Trial.
Brands: SPRING Trial, acute traumatic cervical spinal cord injury